The GLOBE score for patients with Primary Biliary Cholangitis (PBC)

The GLOBE score is an internationally relevant and validated risk assessment tool, able to stratify PBC patients to high and low risk.

Age, years
at initiation of UDCA therapy
   
Total bilirubin level, µmol/L or mg/dl
after one year of UDCA therapy
Upper limit of normal:
Alkaline phosphatase level, U/L
after one year of UDCA therapy
Upper limit of normal:
Albumin, g/L
after one year of UDCA therapy
Lower limit of normal:
Platelets, x 109/L
after one year of UDCA therapy
   

 

Interpretation of the GLOBE score:

Patients with a GLOBE score corresponding with a transplant-free survival comparable with a healthy population are at low risk for future adverse events and patients with a GLOBE score corresponding with a transplant-free survival that significantly deviates from a healthy population may benefit from new therapies.

Data of the healthy population, a population with a life-expectancy comparable with that of other countries participating in the Global PBC Study Group, were retrieved from a Dutch registry (Statistics Netherlands, www.cbs.nl).

The GLOBE score uses age-specific thresholds beyond which survival significantly deviates from an age- and sex matched general population. In subgroups of patients aged 66 years, age-specific GLOBE-score thresholds beyond which survival significantly deviates from matched individuals are 0.52, 0.01, 0.60, 1.01 and 1.69, respectively.